SCHEMBL13797243

SCHEMBL13797243

O=C(O)/C=C/c1ccc2c(c1)CC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
HSD17B10 Q99714 3/20 0.56
CA12 O43570 3/20 0.56
CA1 P00915 3/20 0.56
CA2 P00918 3/20 0.56
CA3 P07451 3/20 0.56
CA4 P22748 3/20 0.56
CA6 P23280 3/20 0.56
CA5A P35218 3/20 0.56
CA7 P43166 3/20 0.56
CA9 Q16790 3/20 0.56
CA14 Q9ULX7 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
MAPK1 P28482 3/20 0.56
AKR1B10 O60218 2/20 0.56
AKR1B1 P15121 2/20 0.56
DPP4 P27487 2/20 0.56
HDAC3 O15379 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30207038 1.00 KDM4E (0.56) KDM4EHSD17B10CA12CA1CA2
SCHEMBL20681307 1.00 KDM4E (0.56) KDM4EHSD17B10CA12CA1CA2
SCHEMBL30567327 1.00 KDM4E (0.56) KDM4EHSD17B10CA12CA1CA2
SCHEMBL30263749 1.00 KDM4E (0.56) KDM4EHSD17B10CA12CA1CA2
SCHEMBL2728401 0.93 KDM4E (0.53) KDM4EHSD17B10CA12CA1CA2
SCHEMBL7615406 0.93 KDM4E (0.53) KDM4EHSD17B10CA12CA1CA2
SCHEMBL7615401 0.93 KDM4E (0.53) KDM4EHSD17B10CA12CA1CA2
SCHEMBL2728405 0.93 KDM4E (0.53) KDM4EHSD17B10CA12CA1CA2
Hydrochloric Acid SCHEMBL27910221 0.91 KDM4E (0.51) KDM4EHSD17B10CA12CA1CA2
SCHEMBL21810677 0.83 KDM4E (0.49) KDM4EHSD17B10CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12084424-B2 Compounds and compositions for treating conditions associated with NLRP activity NOVARTIS AG (CH) 2024-09-10 US disclosed
EP-4349820-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2024-04-10 EP disclosed
EP-3658539-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-02-21 EP disclosed
EP-3880659-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-01-03 EP disclosed
US-20230416211-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-12-28 US disclosed
EP-4279913-A2 ACOUSTIC WAVE SENSORS AND METHODS OF SENSING A GAS-PHASE ANALYT Rohm and Haas Electronic Materials LLC (US) 2023-11-22 EP disclosed
EP-3511709-B1 ACOUSTIC WAVE SENSORS AND METHODS OF SENSING A GAS-PHASE ANALYTE ROHM & HAAS ELECT MAT (US) 2023-11-01 EP disclosed
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-16 US disclosed
US-20230011652-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-01-12 US disclosed
US-11203579-B2 Compounds and compositions for treating conditions associated with NLRP activity NOVARTIS AG (CH) 2021-12-21 US disclosed
EP-3880659-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2021-09-22 EP disclosed
US-20210171477-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2021-06-10 US disclosed
US-10794866-B2 Acoustic wave sensors and methods of sensing a gas-phase analyte ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2020-10-06 US disclosed
WO-2020102576-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed
US-10654816-B2 Compounds and compositions for treating conditions associated with NLRP activity NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-19 US disclosed
US-20200087270-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2020-03-19 US disclosed
US-20190219543-A1 ACOUSTIC WAVE SENSORS AND METHODS OF SENSING A GAS-PHASE ANALYTE U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2019-07-18 US disclosed
EP-3511709-A1 ACOUSTIC WAVE SENSORS AND METHODS OF SENSING A GAS-PHASE ANALYTE Rohm and Haas Electronic Materials LLC (US) 2019-07-17 EP disclosed
US-RE40728-E1 Acid functional polymers based on benzocyclobutene DOW GLOBAL TECHNOLOGIES INC. 2009-06-09 US disclosed
US-RE40728-E1 Acid functional polymers based on benzocyclobutene DOW GLOBAL TECHNOLOGIES INC. 2009-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11203579-B2 Compounds and compositions for treating conditions associated with NLRP activity NLRP3, NLRP1, IAPP KDM4E 4554/4885HSD17B10 3290/4885CA12 3532/4885
US-20200087270-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 KDM4E 4525/4885HSD17B10 1086/4885CA12 2839/4885
US-20210171477-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP3, NLRP1, IAPP KDM4E 4554/4885HSD17B10 3290/4885CA12 3532/4885
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 KDM4E 4486/4885HSD17B10 1041/4885CA12 2844/4885
US-10654816-B2 Compounds and compositions for treating conditions associated with NLRP activity NLRP1, NLRP3, NOD1 KDM4E 4525/4885HSD17B10 1086/4885CA12 2839/4885
US-20230011652-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 KDM4E 4507/4885HSD17B10 932/4885CA12 2983/4885
US-12084424-B2 Compounds and compositions for treating conditions associated with NLRP activity NLRP1, NLRP3, NOD1 KDM4E 4525/4885HSD17B10 1086/4885CA12 2839/4885
US-20230416211-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 KDM4E 4525/4885HSD17B10 1086/4885CA12 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.